financetom
Business
financetom
/
Business
/
Dundee Precious Metals Updates Loma Larga Feasibility Study; Drilling Paused Amid Environmental Concerns
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Dundee Precious Metals Updates Loma Larga Feasibility Study; Drilling Paused Amid Environmental Concerns
Sep 30, 2025 2:58 PM

05:27 PM EDT, 09/30/2025 (MT Newswires) -- Dundee Precious Metals (DPM.TO), after trade Tuesday, released an updated feasibility study and permitting update for its Loma Larga project in Ecuador.

Key results from the study show an after-tax net present value (NPV) of US$488 million with an internal rate of return (IRR) of 18.1%, based on gold at US$1,900 per ounce, silver at US$27.50 per ounce, and copper at US$4 per pound, the company said.

The project is expected to generate strong margins, with a life-of-mine average all-in sustaining cost of US$873 per ounce of gold sold, the company said, adding that "Loma Larga has been designed in line with the highest environmental and water management standards."

The company also said it has paused its planned 23,000-meter drilling program, which was set to begin in the second half of the year. The move comes after some stakeholders in the nearby city of Cuenca raised concerns about the project's environmental impact.

The company received its environmental licence from the Ministry of Environment, Water, and Ecological Transition in the second quarter of 2025, according to the statement.

"The company will continue to engage with stakeholders to address their concerns, and work with the government to understand its expectations for resuming DPM's planned activities," it added.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Neogen's Preliminary Fiscal Q2 Adjusted Earnings Unchanged, Revenue Increases; Fiscal 2025 Sales Outlook Lowered
Neogen's Preliminary Fiscal Q2 Adjusted Earnings Unchanged, Revenue Increases; Fiscal 2025 Sales Outlook Lowered
Jan 10, 2025
07:25 AM EST, 01/10/2025 (MT Newswires) -- Neogen (NEOG) reported preliminary fiscal Q2 adjusted earnings Friday of $0.11 per share, unchanged from a year earlier. Analysts polled by FactSet expected $0.10. Revenue for the quarter ended Nov. 30 was $231.3 million, compared with $229.6 million a year earlier. Analysts polled by FactSet expected $227.2 million. The company said it now...
Pfizer Says Sasanlimab Combination Prolongs Event-Free Survival in Phase 3 Bladder Cancer Trial
Pfizer Says Sasanlimab Combination Prolongs Event-Free Survival in Phase 3 Bladder Cancer Trial
Jan 10, 2025
07:25 AM EST, 01/10/2025 (MT Newswires) -- Pfizer ( PFE ) said Friday that its pivotal phase 3 trial evaluating sasanlimab in combination with Bacillus Calmette-Guerin, or BCG, as treatment for non-muscle invasive bladder cancer achieved its primary endpoint of event-free survival. The study showed that the combination therapy provided a clinically meaningful and statistically significant improvement compared with BCG...
Tilray Brands' Fiscal Q2 Loss Widens, Revenue Increases; Reaffirms 2025 Revenue Guidance
Tilray Brands' Fiscal Q2 Loss Widens, Revenue Increases; Reaffirms 2025 Revenue Guidance
Jan 10, 2025
07:29 AM EST, 01/10/2025 (MT Newswires) -- Tilray Brands ( TLRY ) reported a fiscal Q2 net loss Friday of $0.10 per diluted share, wider than a loss of $0.07 a year earlier. Analysts polled by FactSet expected a loss of $0.03. Revenue for the quarter ended Nov. 30 was $211 million, compared with $193.8 million a year earlier. Analysts...
Royalty Pharma simplifies corporate structure with $1.1 bln deal
Royalty Pharma simplifies corporate structure with $1.1 bln deal
Jan 10, 2025
Jan 10 (Reuters) - Royalty Pharma ( RPRX ) said on Friday it would pay about $1.1 billion to acquire RP Management, an organization that manages its operations as the healthcare firm seeks to simplify corporate structure. Royalty Pharma ( RPRX ) buys royalties of future drugs from academic labs and biotechnology companies, which in turn use the cash to...
Copyright 2023-2026 - www.financetom.com All Rights Reserved